Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BLFS shares. Benchmark cut shares of BioLife Solutions from a "buy" rating to a "hold" rating in a research note on Monday, August 10th. HC Wainwright lowered shares of BioLife Solutions from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $32.00 to $31.00 in a research report on Thursday, July 23rd. Lake Street Capital cut shares of BioLife Solutions from a "buy" rating to a "hold" rating and dropped their target price for the company from $33.00 to $31.00 in a report on Wednesday, July 22nd. Jefferies Financial Group downgraded shares of BioLife Solutions from a "buy" rating to a "hold" rating and lifted their price target for the company from $30.00 to $31.00 in a research report on Thursday, July 23rd. Finally, Maxim Group lowered BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $31.38.

BioLife Solutions Stock Performance

The firm has a market capitalization of $1.86 billion, a PE ratio of 32.85 and a beta of 1.93. The firm's 50-day moving average is $30.34 and its 200 day moving average is $24.88.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.88. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. The firm had revenue of $28.47 million during the quarter, compared to the consensus estimate of $27.80 million. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post 0.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its position in shares of BioLife Solutions by 3,057.9% in the second quarter. California State Teachers Retirement System now owns 1,215,252 shares of the medical equipment provider's stock valued at $34,319,000 after purchasing an additional 1,176,769 shares during the period. AXQ Capital LP purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $203,000. Strait & Sound Wealth Management LLC purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $95,000. Ranger Investment Management L.P. acquired a new position in shares of BioLife Solutions during the 2nd quarter valued at about $6,736,000. Finally, Summit Creek Advisors LLC acquired a new position in shares of BioLife Solutions during the 2nd quarter valued at about $5,099,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions NASDAQ: BLFS specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Before you consider BioLife Solutions, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.

While BioLife Solutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.